ESZOPICLONE (eszopiclone) by Aurobindo Pharma is unclear; however, its effect could be related to its interaction with gaba-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors. Approved for insomnia. First approved in 2023.
Drug data last refreshed 19h ago
unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.
Modified Suanzaoren Decoction Versus Eszopiclone for the Treatment of Chronic Insomnia Disorder
Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients
Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients
A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)
Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fed Conditions
Worked on ESZOPICLONE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.